Researchers have used a powerful new CRISPR activation library to pinpoint a previously unknown gene that makes blood cancer cells resistant to a leading drug. The same screen also turned up several genes that appear to accelerate lymphoma growth, according to a report from Medical Xpress.
The tool works by activating genes across the genome, allowing researchers to see which ones confer drug resistance or drive faster cancer growth. The newly identified resistance gene had not been linked to this effect before, suggesting a fresh avenue for understanding why some patients stop responding to treatment.
While the source does not name the specific drug or cancer subtype, the findings highlight how CRISPR activation screens can reveal hidden genetic drivers. The authors note that these genes could serve as targets for future therapies, potentially helping to overcome resistance or slow lymphoma progression.